Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAGESIC-12 vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Management of persistent, moderate to severe chronic pain in opioid-tolerant patients requiring around-the-clock analgesic therapy for an extended period,Management of breakthrough pain in opioid-tolerant patients
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Terminal elimination half-life is approximately 20–27 hours (range 13–44 hours) after transdermal patch removal; prolonged in elderly, hepatic impairment, and with continuous use due to drug accumulation in skin and adipose tissue.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Fentanyl is primarily metabolized in the liver via CYP3A4-mediated N-dealkylation to norfentanyl, an inactive metabolite. Approximately 75% of the dose is excreted in urine, mainly as metabolites, with less than 10% as unchanged drug.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Renal: approximately 75% as metabolites (primarily norfentanyl and other inactive metabolites) and <10% as unchanged fentanyl; fecal: approximately 9%; biliary: minor.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Approximately 80–85% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Approximately 6 L/kg (range 3–8 L/kg) after intravenous administration; high Vd indicates extensive tissue distribution and accumulation in fat and muscle.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Transdermal: approximately 92% relative to intravenous; absolute bioavailability is about 30–40% (due to first-pass metabolism, but transdermal bypasses hepatic first-pass, hence high relative bioavailability).
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
GFR 30-89 m L/min: start at 50% of usual initial dose; GFR <30 m L/min: avoid use or start at 50% of usual dose with cautious titration. Not recommended in dialysis patients.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
Child-Pugh class A: start at 50% of usual initial dose; Child-Pugh class B: start at 25% of usual dose; Child-Pugh class C: avoid use due to extreme risk of toxicity.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
For pediatric patients aged 2-16 years currently receiving and tolerant to opioids (equivalent to at least 60 mg oral morphine/day): initial fentanyl dose (mcg/h) based on previous 24-hour opioid requirement using standard conversion; apply patch every 72 hours. For opioid-naive pediatric patients: not recommended.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
Initiate at 50% of usual adult starting dose (e.g., 12 mcg/h every 72 hours) due to increased sensitivity and reduced clearance; titrate cautiously with longer intervals between dose adjustments.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; ABUSE POTENTIAL; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISK OF MEDICATION ERRORS; and RISK OF SERIOUS HARM OR DEATH WITH CONCOMITANT USE OF CYP3A4 INHIBITORS. DURAGESIC is contraindicated in the management of acute or intermittent pain, or in opioid-non-tolerant patients. Accidental exposure to DURAGESIC may result in fatal respiratory depression.
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
Life-threatening respiratory depression, especially during initiation or dose escalation,Accidental exposure can be fatal,Risk of abuse, misuse, and addiction,Risks from concomitant use with benzodiazepines or other CNS depressants,Neonatal opioid withdrawal syndrome with prolonged use during pregnancy,Risks of medication errors (e.g., confusion with other fentanyl products),Serotonin syndrome with concomitant serotonergic drugs,Adrenal insufficiency,Severe hypotension,Risks in patients with head injury or increased intracranial pressure,Application site reactions and skin irritation,Wound healing complications in patients with surgical wounds
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Opioid non-tolerant patients,Management of acute or intermittent pain,Postoperative pain management,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to fentanyl or any components of the system
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
Avoid or limit grapefruit juice as it inhibits CYP3A4, increasing fentanyl levels and risk of adverse effects. No other significant food interactions. Alcohol should be avoided as it enhances central nervous system depression.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdrawal syndrome, respiratory depression, and decreased fetal growth; avoid prolonged use near term.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Fentanyl transfers into breast milk; M/P ratio approximately 0.17-0.47. Caution: risk of infant sedation and respiratory depression. Consider benefits vs risks; avoid if infant is <3 months or has respiratory compromise.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
Pregnancy increases clearance of fentanyl by 35-50% in second and third trimesters; consider dose increase guided by pain response; postpartum clearance returns to prepregnancy levels within 48 h, requiring dose reduction.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
DURAGESIC-12 (fentanyl transdermal system) is indicated for opioid-tolerant patients only. Do not initiate in opioid-naive patients due to risk of fatal respiratory depression. Apply to non-irritated, non-irradiated skin on flat surface such as chest, back, flank, or upper arm. Avoid heat sources (heating pads, hot tubs, fever) which increase absorption. Monitor for constipation and respiratory depression, especially at start and dose titration. Not for acute pain or post-op use in opioid-naive patients.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Apply patch to clean, dry, non-hairy skin; do not cut or damage the patch.,Do not expose patch to direct heat (heating pads, hot tubs, electric blankets).,Keep patch away from children and pets; dispose of used patches by folding adhesive side together and flushing down toilet.,Do not drink grapefruit juice as it may increase fentanyl levels.,Do not stop using patch suddenly as withdrawal symptoms may occur.,Report severe drowsiness, confusion, difficulty breathing, or constipation.,Store at room temperature away from moisture and heat.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAGESIC-12 vs ALFENTANIL, answered by our medical review team.
DURAGESIC-12 is a Opioid Analgesic that works by Fentanyl is a potent synthetic opioid agonist that primarily binds to mu-opioid receptors in the central nervous system, leading to analgesic effects by increasing potassium conductance and decreasing calcium influx, thereby inhibiting ascending pain pathways and altering pain perception.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAGESIC-12 and ALFENTANIL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAGESIC-12 is: Transdermal patch, initially 12 mcg/h applied every 72 hours in opioid-naive patients; titrate based on response and tolerance.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAGESIC-12 and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAGESIC-12 is classified as Category C. Pregnancy category C. First trimester: Limited data; theoretical risk of neural tube defects if folate deficiency exacerbated. Second and third trimesters: Risk of neonatal withdra. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.